A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
Condition: Hepatitis C Virus InfectionInterventions: Drug: Daclatasvir; Drug: Asunaprevir; Drug: Ribavirin; Biological: pegIFNα-2b; Drug: TelaprevirSponsor: Bristol-Myers SquibbActive, not recruiting - verified April 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2012 Category: Research Source Type: clinical trials
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
Condition: Hepatitis C Virus InfectionInterventions: Drug: Daclatasvir; Drug: Asunaprevir; Drug: Ribavirin; Biological: pegIFNα-2b; Drug: TelaprevirSponsor: Bristol-Myers SquibbCompleted - verified April 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 29, 2012 Category: Research Source Type: clinical trials
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
Condition: Hepatitis C Virus InfectionInterventions: Drug: Daclatasvir; Drug: Asunaprevir; Drug: Ribavirin; Biological: pegIFNα-2b; Drug: TelaprevirSponsor: Bristol-Myers SquibbActive, not recruiting - verified April 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 29, 2012 Category: Research Source Type: clinical trials
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
Condition: Hepatitis CInterventions: Drug: Telaprevir; Drug: Peginterferon alfa-2b; Drug: RibavirinSponsors: Vertex Pharmaceuticals Incorporated; Janssen PharmaceuticalsCompleted - verified May 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2012 Category: Research Source Type: clinical trials
